Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies

Abstract

PurposeOvarian cancer is a devastating disease and biomarkers for its early diagnosis are urgently required. Serum may be a valuable source of biomarkers that may be revealed by proteomic profiling. Herein, complementary serum protein profiling strategies were employed for discovery of biomarkers that could discriminate cases of malignant and benign ovarian cancer.Experimental designIdentically collected and processed serum samples from 22 cases of invasive epithelial ovarian cancer, 45 benign ovarian neoplasms, and 64 healthy volunteers were subjected to immunodepletion and protein equalization coupled to 2D‐DIGE/MS and multidimensional fractionation coupled to SELDI‐TOF profiling with MS/MS for protein identification. Selected candidates were verified by ELISA in samples from malignant (n = 70) and benign (n = 89) cases and combined marker panels tested against serum CA125.ResultsBoth profiling platforms were complementary in identifying biomarker candidates, four of which (A1AT, SLPI, APOA4, VDBP) significantly discriminated malignant from benign cases. However, no combination of markers was as good as CA125 for diagnostic accuracy. SLPI was further tested as an early marker using prediagnosis serum samples. While it rose in cases toward diagnosis, it did not discriminate prediagnosis cases from controls.Conclusions and clinical relevanceThe candidate biomarkers warrant further validation in independent sample sets.

Detection of Epithelial Ovarian Cancer using C8Magnetic Bead Separation and MALDI-TOF Plasma Proteome Profiling in Egyptian Females

“…In our study, we identified a proteomic profile of 21 peaks that can discriminate between patients with epithelial ovarian cancer and healthy controls. Of these, peaks 3,475.57 and 2,939.07 could be related to peaks 3,470 and 2,937 respectively, in the proteomic profile identified by Fan et al, (2010), Peak 6,630.54, in our profile, could be related to peak 6646.1 identified by Timms et al, (2014) and to peak 6,635.1 identified by Qiu et al, (2009). Our results showed that a 5-peak profile could discriminate epithelial ovarian cancer from benign ovarian masses.…”

Circulating long non‑coding RNAs HULC and ZNFX1‑AS1 are potential biomarkers in patients with gastric cancer

“…Thus, improving the early discovery, diagnosis and treatment is essential to increase the survival rate of gastric cancer patients. Certain serum biomarkers, such as CA-125 and CEA, are known to have a potential capacity to detect specific types of cancer at an early stage (19). However, the sensitivity and specificity of such traditional serum biomarkers for gastric cancer is low and does not satisfy the clinical diagnostic requirements (20).…”

Liquid‐phase based separation systems for depletion, prefractionation, and enrichment of proteins in biological fluids and matrices for in‐depth proteomics analysis—An update covering the period 2014–2016

“…Protein equalization and immunodepletion coupled to 2D‐DIGE/MS and multidimensional fractionation coupled to SELDI‐TOF profiling with MS/MS for protein identification in serum has been proposed . The pooled sera samples were first immunodepleted of seven HAPs using the HPLC‐based MARS, followed by simultaneously reducing HAPs concentration and enhancing LAPs concentration using ProteoMiner protein enrichment.…”